Cytokines; Diabetes Mellitus, Type 2/complications; Fatty Acids, Nonesterified; Fatty Liver/diagnosis/etiology/therapy; Humans; Insulin Resistance; Leptin; Obesity/complications; Oxidative Stress; Prognosis; Weight Loss
Abstract :
[en] Non-alcoholic steatohepatitis (NASH) is a disease of emerging identity and importance. It is frequently associated with obesity, especially visceral fat, and is intimately related to fatty liver and markers of the insulin resistance syndrome. Both the prevalence and the severity of liver steatosis are related to body mass index, waist circumference, hyperinsulinaemia, hypertriglyceridaemia and impaired glucose tolerance or type 2 diabetes. The identification of obese patients who may progress from steatosis to NASH and from NASH to fibrosis/cirrhosis is an important clinical challenge. Substantial weight loss is accompanied by a marked attenuation of insulin resistance and related metabolic syndrome and, concomitantly, by a remarkable regression of liver steatosis in most patients, although increased inflammation may be detected in some subjects. Thus, NASH may be considered as another disease of affluence, as is the insulin resistance syndrome, and perhaps being part of it, especially in obese patients.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Luyckx, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Language :
English
Title :
Obesity and liver disease.
Publication date :
2002
Journal title :
Best Practice and Research. Clinical Endocrinology and Metabolism
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Sheth SG, Gordon FD & Chopra S. Nonalcoholic steatohepatitis. Annals of Internal Medicine 1997; 126: 137-145.
Day CP. Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut 2002; 50: 585-588.
Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Seminars in Liver Disease 2001; 21: 3-16.
Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Digestive Diseases 1999; 17: 80-89.
Falck-Ytter Y, Younossi ZM, Marchesini G & McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars in Liver Disease 2001; 21: 17-26.
McCullogh AJ. Update on nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology 2002; 34: 255-262.
Ludwig J, Viggiano TR, McGill DB & Ott B. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clinical Proceedings 1980; 55: 434-438.
James O & Day C. Non-alcoholic steatohepatitis: Another disease of affluence. Lancet 1999; 353: 1634-1636.
Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
Guzzaloni G, Grugni G, Minocci A et al. Liver steatosis in juvenile obesity: Correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. International Journal of Obesity 2000; 24: 772-776.
Rashid M & Roberts EA. Nonalcoholic steatohepatitis in children. Journal of Pediatric Gastroenterology and Nutrition 2000; 30: 48-53.
Mukai M, Ozasa K, Hayashi K & Kawai K. Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Digestive Diseases and Sciences 2002; 47: 549-555.
Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
Garcia Monzon C, Martin-Perez E, Iacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. Journal of Hepatology 2000; 33: 716-724.
Dixon JB, Bhathal PS & O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
Chitturi S & Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Seminars in Liver Disease 2001; 21: 27-41.
Day CP & James OFW. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998; 114: 842-845.
Van Steenbergen W & Lanckmans S. Liver disturbances in obesity and diabetes mellitus. International Journal of Obesity 1995; 19 (supplement 3): S27-S36.
Day CP & James OF. Hepatic steatosis: Innocent bystander or guilty party? Hepatology 1998; 27: 1463-1466.
Scheen AJ, Paquot N, Letiexhe M et al. Glucose metabolism in obesity: Lessons from OGTT, IVGTT, and clamp studies. International Journal of Obesity 1995; 19 (supplement 3): S14-S20.
Meek SE, Nair KS & Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999; 48: 10-14.
Peiris AN, Mueller RA, Smith GA et al. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. Journal of Clinical Investigation 1986; 78: 1648-1657.
Goto T, Onuma T, Takebe K & Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. International Journal of Obesity 1995; 19: 841-845.
Tobe K, Ogura T, Tsukamoto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. American Journal of Gastroenterology 1999; 94: 3328-3335.
Uygun A, Kadayifci A, Yesilova Z et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. American Journal of Gastroenterology 2000; 95: 3584-3589.
Lee Y, Wang MY, Kakuma T et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. Journal of Biological Chemistry 2001; 276: 5629-5635.
Saxena NK, Ikeda K, Rockey DC et al. Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-771.
Tilg H & Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. New England Journal of Medicine 2000; 343: 1467-1476.
Hotamisligil GH & Spiegelman BM. Tumor necrosis factor α. A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280.
Wigg AJ, Roberts-Thomson IC, Dymock RB et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumour necrosis α in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001; 48: 206-211.
Nair S, Cope K, Terence RH & Diehl AM. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis. American Journal of Gastroenterology 2001; 96: 1200-1204.
Sanyal AJ, Campbell-Sargent C, Mirshani F et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
Yang S, Zhu H, Li YB et al. Mitochondrial adaptations to obesity-related oxidant stress. Archives of Biochemistry and Biophysics 2000; 378: 259-268.
Mendler MH, Turlin B, Moirand B et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1157-1163.
MacDonald GA & Powell LW. More clues to the relationship between hepatic iron and steatosis. An association with insulin resistance? Editorial. Gastroenterology 1999; 117: 1241-1244.
George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318.
Guillygomarc'h A, Mendler MH, Moirand R et al. Venesection therapy of insulin-resistance-associated hepatic iron overload. Journal of Hepatology 2001; 35: 344-349.
Facchini FS, Hua NW & Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-939.
Zelman S. The liver in obesity. Archives of Internal Medicine 1952; 90: 141-156.
Nasrallah SM, Wills CEJ & Galambos JT. Hepatic morphology in obesity. Digestive Diseases and Sciences 1981; 26: 325-327.
Braillon A, Capron JP, Hervé MA et al. Liver in obesity. Gut 1985; 26: 133-139.
Clain D & Lefkowitch J. Fatty liver disease in morbid obesity. Gastroenterology Clinics of North America 1987; 16: 239-252.
Kern WH, Heger AH & Payne JH. Fatty metamorphosis of the liver in morbid obesity. Archives of Pathology 1973; 96: 342-346.
Manes JL, Taylor HB & Starkloft GB. Relationship between hepatic morphology and clinical and biochemical findings in morbidly obese patients. Journal of Clinical Pathology 1973; 26: 776-783.
Galambos JT & Wills CE. Relationship between 505 paired liver tests and biopsies in 242 obese patients. Gastroenterology 1978; 74: 1191-1195.
Alder M & Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. American Journal of Medicine 1979; 67: 811-816.
Naveau S, Giraud V, Borotto E et al. Excess weight as a risk factor for alcoholic liver disease. Hepatology 1997; 26: 108-111.
Hourigan LF, MacDonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219.
McCullough AJ & Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease (editorial). Hepatology 1999; 29: 1328-1330.
Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
Andersen T & Gluud C. Liver morphology in morbid obesity: A literature survey. International Journal of Obesity 1984; 8: 97-106.
Luyckx FH, Lefèbvre PJ & Scheen AJ. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss. Diabetes & Metabolism 2000; 26: 98-106.
Andersen T, Christoffersen P & Gluud C. The liver in consecutive patients with morbid obesity: A clinical, morphological, and biochemical study. International Journal of Obesity 1984; 8: 107-115.
Klain J, Fraser D, Goldstein J et al. Liver histology abnormalities in the morbidly obese. Hepatology 1989; 10: 873-876.
Wanless IR & Lentz JS. Fatty liver steatosis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
Marceau P, Biron S, Hould FS et al. Liver pathology and the metabolic syndrome X in severe obesity. Journal of Clinical Endocrinology and Metabolism 1999; 84: 1513-1517.
Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: Effects of drastic weight loss after gastroplasty. International Journal of Obesity 1998; 22: 222-226.
Rinella ME, Alonso E, Rao S et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transplantation 2001; 7: 409-414.
Kral J, Schaffner F, Pierson R & Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548-551.
Banerji MA, Buckley MC, Chaiken RL et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. International Journal of Obesity 1995; 19: 846-850.
Knobler H, Schattner A, Zhornicki T et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. Quarterly Journal of Medicine 1999; 92: 73-79.
Kissebah AH & Krakower GR. Regional adiposity and morbidity. Physiological Reviews 1994; 7: 761-811.
Barzilai N, Liu BQ, Vuguin P et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48: 94-98.
Song S. The role of increased liver triglyceride content: A culprit of diabetic hyperglycaemia? Diabetes/Metabolism Research and Reviews 2002, 18: 5-12.
Nagore N & Scheuer PJ. The pathology of diabetic hepatitis. Journal of Pathology 1998; 156: 155-160.
Silverman JF, O'Brien KF, Long S et al. Liver pathology in morbidly obese patients with and without diabetes. American Journal of Gastroenterology 1990; 85: 1349-1355.
Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
Marchesini G, Brizi M, Morselli-Labate AM et al. Association of non-alcoholic fatty liver disease with insulin resistance. American Journal of Medicine 1999; 107: 450-455.
Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
Cortez-Pinto H, Camilo ME, Baptista A et al. Non-alcoholic fatty liver: Another feature of the metabolic syndrome? Clinical Nutrition 1999; 18: 353-358.
Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
Oehler G, Bleyl H & Matthes KJ. Hyperinsulinemia in hepatic steatosis. International Journal of Obesity 1982; 6 (supplement 1): 137-144.
Luyckx FH, Scheen AJ, Desaive C et al. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes & Metabolism 1998; 24: 355-361.
Willner IR, Water B, Patil SR et al. Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. American Journal of Gastroenterology 2001; 96: 2957-2961.
Teli MR, James OFW, Burt AD et al. The natural history of non-alcoholic fatty liver: A follow-up study. Hepatology 1995; 22: 1714-1719.
Caldwell SH, Oelsner DH, Lezzoni JC et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
Poonawala A, Nair SP & Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology 2000; 32: 689-692.
Struben VMD, Hespenheide EE & Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. American Journal of Medicine 2000; 108: 9-13.
Bernard S, Touzet S, Personne I et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes. Diabetologia 2000; 43: 995-999.
Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-744.
Charlton M, Kasparova P, Weston S et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplantation 2001; 7: 608-614.
Brolin RE, Bradley LJ & Taliwal RV. Unsuspected cirrhosis discovered during elective obesity operations. Archives of Surgery 1998; 133: 84-88.
Angulo P & Lindor KD. Treatment of nonalcoholic fatty liver: Present and emerging therapies. Seminars in Liver Disease 2001; 21: 81-88.
Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Journal of Hepatology 1997; 27: 103-107.
Fong DG, Nehra V, Lindor K & Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10.
Scheen AJ & Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Reviews 1999; 7: 77-93.
Li HZ, Yang SQ, Chuckaree C et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Medicine 2000; 6: 998-1003.
Marchesini G, Brizi M, Bianchi G et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
Saltiel AR & Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
Caldwell SH, Hespenheide EE, Redick JA et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. American Journal of Gastroenterology 2001; 96: 519-525.
Scheen AJ. Hepatotoxicity with thiazolidinediones: Is it a class effect? Drug Safety 2001; 24: 873-888.
Drenick EJ, Simmons F & Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. New England Journal of Medicine 1970; 282: 829-834.
Andersen T, Gluud C, Franzmann MB & Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. Journal of Hepatology 1991; 12: 224-229.
Vyberg M, Ravn V & Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver 1987; 7: 271-276.
Silverman EM, Sapala JA & Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. American Journal of Clinical Pathology 1995; 104: 23-31.
Luyckx FH, Scheen AJ, Desaive C et al. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity (letter). Journal of Clinical Endocrinology and Metabolism 1999; 84: 4293.
Letiexhe MR, Scheen AJ, Gérard PL et al. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. Journal of Clinical Endocrinology and Metabolism 1995; 89: 393-399.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
